Pituitary adenylate cyclase-activating polypeptide (PACAP38) modulates lymphocyte and macrophage functions: Stimulation of adherence and opposite effect on mobility

Neuropeptides

Volumn 30, Issue 6, 1996, Pages 583-595

  Garrido, E ^a   Delgado, M ^a   Martinez C ^a   Gomariz, R P ^a   De La Fuente, M ^a  

^a UNIVERSIDAD COMPLUTENSE DE MADRID   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

FORSKOLIN; HYPOPHYSIS ADENYLATE CYCLASE ACTIVATING POLYPEPTIDE; PHORBOL ESTER; PROTEIN KINASE C; PROTEIN KINASE INHIBITOR;

ANIMAL CELL; ARTICLE; CELL ADHESION; CELL MOTILITY; CHEMOTAXIS; CONTROLLED STUDY; LYMPHOCYTE; MACROPHAGE; MALE; NONHUMAN; PRIORITY JOURNAL; RAT;

ANIMALIA;

EID: 0030456783     PISSN: 01434179     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0143-4179(96)90042-6     Document Type: Article

References (67)

1. Blalock J E. The syntax of immune-neuroendocrine communication. Immunol Today 1994; 15: 504-511.
2. Miyata A, Arimura A, Dahl R R et al. Isolation of a novel 38 residue-hypothalamic polypeptide which simulates adenylate cyclase in pituitary cells. Biochem Biophys Res Comm 1989; 164: 567-574.
3. Arimura A. Pituitary adenylate cyclase activating polypeptide (PACAP): discovery and current status of research. Regul Pept 1992; 37: 287-303.
4. Gaytan F, Martinez-Fuentes A J, Gracia-Navarro F, Vaudry H, Aguilar E. Pituitary adenylate cyclase-activating peptide (PACAP) immuno-localization in lymphoid tissues of the rat. Cell Tissue Res 1994; 276: 233-277
5. Tatsuno I, Gottschall P E, Arimura A. Inhibition of mitogen-stimulated proliferation of murine splenocytes by a novel neuropeptide, pituitary adenylate cyclase-activating polypeptide: a comparative study with vasoactive intestinal peptide. Endocrinology 1991; 128: 728-734.
6. Ichinose M, Asai M, Imai K, Sawada M. Enhancement of phagocytosis in mouse macrophages by pituitary adenylate cyclase activating polypeptide (PACAP) and related peptides. Immunopharmacology 1995; 30: 217-224.
7. Delgado M, De la Fuente M, Martinez C, Gomariz R P. Pituitary adenylate cyclase-activating polypeptides (PACAP27 and PACAP38) inhibit the mobility of murine thymocytes and splenic lymphocytes: comparison with VIP and implication of cAMP. J Neuroimmunol 1995; 62: 137-146.
8. + thymocytes from glucocorticoid- induced apoptosis. Blood 1996; 87: 5152-5161.
9. Cauvin A, Robberecht P, De Neef P et al. Properties and distribution of receptors for pituitary adenylate cyclase activating peptide (PACAP) in rat brain and spinal cord. Regul Pept 1991; 35: 161-173.
10. Shivers B D, Göres T J, Gottschall P E, Arimura A. Two high affinity binding sites for pituitary adenylate cyclase-activating polypeptide have different tissue distributions. Endocrinology 1991; 128: 3055-3065.
11. O'Dorisio M S, Hermina I U S, O'Dorisio T M, Bacerzak S P. Vasoactive intestinal polypeptide modulation of lymphocyte adenylate cyclase. J Immunol 1981; 127: 2551-2556.
12. Rawlings S R. PACAP, PACAP receptors, and intracellular signalling. Mol Cell Endocrinol 1994; 101: C5-C9.
13. i in rat gonadotrophs throgh an inositol triphosphate-dependent mechanism. J Biol Chem 1994; 269: 5680-5686.
14. Doherty D E, Haslett C, Tonnesen M G, Henson P M. Human monocyte adherence: A primary effect of chemotactic factors on the monocyte to stimulate adherence to human endothelium. J Immunol 1987; 138: 1762-1771.
15. Springer T A. Adhesion receptors of the immune system. Nature 1990; 346: 425-433.
16. Mackay C R, Imhof B A. Cell adhesion in the immune system. Immunol Today 1993; 14: 99-102.
17. De la Fuente M, Delgado M, Del Rio M, Martinez C, Hernanz A, Gomariz R P. Stimulation by vasoactive intestinal peptide (VIP) of phagocytic function in rat peritoneal macrophages. Protein kinase C involvement. Regul Pept 1993; 48: 347-353.
18. De la Fuente M, Delgado M, Del Rio M et al. Vasoactive intestinal peptide modulation of adherence and mobility in rat peritoneal lymphocytes and macrophages. Peptides 1994; 15: 1157-1163.
19. De la Fuente M, Del Rio M, Fernandez M D, Hernanz A. Modulation of phagocytic function in murine peritoneal macrophages by bombesin, gastrin-releasing peptide and neuromedin C. Immunology 1991; 73: 205-211.
20. Noga S J, Norman S J, Weiner R S. Methods in laboratory investigation: Isolation of guinea pigs monocytes and Kurloff cells. Characterization of monocyte subsets by morphologic, cytochemistry, and adherence. Lab Invest 1984; 51: 244-249.
21. Boyden S V. The chemotactic effect of mixtures of antibody and antigen on polymorphonuclear leukocytes. J Exp Med 1962; 115: 453-458.
22. Schiffman E, Gallin J I. Biochemistry of phagocyte chemotaxis. Curr Top Cell Regul 1979; 15: 203-261.
23. Schubert T, Müller W E. N-formyl-Met-Leu-Phe induced accumulation of inositol triphosphates indicates the presence of oligopeptide chemoattractant receptors on circulating human lymphocytes. FEES Lett 1989; 257: 174-176.
24. Boige N, Aminanoff B, Munck A, Laburthe M. Forskolin stimulates adenylate cyclase in human colonic crypts: Interaction with VIP. Eur J Pharmacol 1984; 101: 111-117.
25. Taffet S M, Greenfield A R L, Haddox M K. Retinal inhibits TPA activated calcium-dependent, phospholipid-dependent protein kinase C. Biochem Biophys Res Comm 1983; 114: 1194-1199.
26. 2 as a VIP antagonist. Endocrinology 1985; 116: 2643-2649.
27. Unanue E, Allen P. The basis for the immunoregulatory role of macrophages and other accessory cells. Science 1987; 236: 551-557.
28. Christophe J. Type I receptors for PACAP (a neuropeptide even more important than VIP?). Biochim Biophys Acta 1993; 1154: 183-199.
29. Ottaway C A. Receptors for vasoactive intestinal peptide on murine lymphocytes turn over rapidly. J Neuroimmunol 1992; 38: 241-254.
30. Haskill S, Johnson C, Eierman D, Becker S, Warren K. Adherence induces selective mRNA expression of monocyte mediators and proto-oncogenes. J Immunol 1988; 140: 1690-1694.
31. De la Fuente M, Bernaez Y, Del Rio M, Hernanz A. Stimulation of murine peritoneal macrophage functions by neuropeptide Y and peptide YY. Involvement of protein kinase C. Immunology 1993; 80: 259-265.
32. De la Fuente M, Garrido J J, Arahuetes R M, Hernanz A. Stimulation of phagocytic function in mouse macrophages by neurotensin and neuromedin N. J Neuroimmunol 1993; 42: 97-104.
33. Garrido J J, Arahuetes R M, Hernanz A, De la Fuente M. Modulation of neurotensin and neuromedin N of adherence and chemotaxis capacity of murine lymphocytes. Regul. Pept. 1992; 41: 27-37.
34. De la Fuente M, Campos M, Del Rio M, Hernanz A. Inhibition of murine peritoneal macrophage functions by sulfated cholecystokinin octapeptide. Regul Pept 1995; 55: 47-56.
35. Bondesson L, Nordlind K, Liden S, Gafvelin G, Theodorsson E, Mutt V. Dual effects of vasoactive intestinal peptide (VIP) on leukocyte migration. Acta Physiol Scand 1991; 141: 477-481.
36. Sacerdote P, Ruff M R, Pert C B. Vasoactive intestinal peptide 1-12: a ligand for the CD4 (T4)/human immunodeficiency virus receptor. J Neurosci Res 1987; 18: 102-107.
37. Del Rio M, De la Fuente M. Chemoattractant capacity of bombesin, gastrin-releasing peptide and neuromedin C is mediated through PKC activation in murine peritoneal leukocytes. Regul Pept 1994; 49: 185-193.
38. Ruff M R, Wahl S M, Pert C B. Substance P receptor-mediated chemotaxis of human monocytes. Peptides 1985; 6: 107-111.
39. Bourne H C, Lichtenstein L M, Melmon K L, Henney C S, Weinstein Y, Shearer G M. Modulation of inflammation and immunity by cyclic AMP. Science 1974; 184: 19-28.
40. Gallin JI, Sandler J A, Clyman R I, Manganiello V C, Vaughan M. Agents that increase cyclic AMP inhibit accumulation of cGMP and depress human monocyte locomotion. J Immunol 1978; 120: 492-496.
41. Pryzwansky K B, Stainer A L, Spitznagel J K, Kapoor C L. Compartmentalization of cyclic AMP during phagocytosis by human neutrophilic granulocytes. Science 1981; 211: 407-410.
42. Wirth J J, Kierszenbaum F. Inhibitory action of elevated levels of adenosine-3́:5́ cyclic monophosphate on phagocytosis: effects on macrophage-trypanosoma cruzi interaction. J Immunol 1982; 129: 2759-2762.
43. Rivkin Y, Rosenblatt J, Becker E L. The role of cyclic AMP in the chemotactic responsiveness and spontaneous motility of rabbit peritoneal neutrophils. J Immunol 1975; 115: 1126-1134.
44. Scheiner G F, Unanue E R. The modulation of spontaneous and anti-Ig-stimulated mobility of lymphocytes by cyclic nucleotides and adrenergic and cholinergic agents. J Immunol 1975; 114: 802-808.
45. Moore T C, Lachman P J. Cyclic AMP reduces and cyclic GMP increases the traffic of lymphocytes through peripheral lymph node of sheep in vivo. Immunology 1982; 47: 423-429.
46. Hatch G E, Nichols W K, Hill H R. Cyclic nucleotic changes in human neutrophils induced by chemoattractants and chemotactic modulators. J Immunol 1977; 119: 450-456.
47. Smith J W, Steiner A L, Parker C W. Human lymphocyte metabolism. Effects of cyclic and monocyclic nucleotides on stimulation by phytohemagglutinin. J Clin Invest 1971; 50: 442-448.
48. Watson J. The involvement of cyclic nucleotide metabolism in the initiation of lymphocyte proliferation induced by mitogens. J Immunol 1976; 117: 1656-1663.
49. Betz M, Fox B S. PGE2 inhibits production of TH1 but not TH2 lymphokines. J Immunol 1991; 146: 108-113.
50. Iwaz J, Lafont S, Revillard J P. Elevation of cyclic 3́5́ adenosine monophosphate levels by cholera toxin inhibits the generation of interleukin-2 activity. Cell Immunol 1986; 102: 455-461.
51. Calvo J R, Guerrero J M, Molinero P, Blasco R, Goberna R. Interaction of vasoactive intestinal peptide (VIP) with human peripheral blood lymphocytes: Specific binding and cyclic AMP production. Gen Pharmacol 1986; 17: 185-189.
52. Gomariz R P, Garrido E, Leceta J, Martinez C, Abalo R, Delgado M. Gene expression of VIP receptor in rat lymphocytes. Biochem Biophys Res Comm 1994; 203: 1599-1605.
53. Guerrero J M, Prieto J C, Elorza F L, Ramirez F, Goberna R. Interaction of vasoactive intestinal peptide with human blood mononuclear cells. Mol Cell Endocrinol 1981; 21: 151-159.
54. Calvo J R, Montilla M L, Guerrero J M, Segura J J. Expression of VIP receptors in mouse peritoneal macrophages: Functional and molecular characterization. J Neuroimmunol 1994; 50: 85-93.
55. Segura J J, Guerrero J M, Goberna R, Calvo J R. Characterization of functional receptors for vasoactive intestinal peptide (VIP) in rat peritoneal macrophages. Regul Pept 1991; 33: 133-143.
56. Delgado M, Pozo D, Martinez C et al. Characterization of gene expression of VIP and VIP1-receptor in rat peritoneal lymphocytes and macrophages. Regul Pept 1996; 62: 161-166.
57. Ishihara T, Shigemoto R, Mori K, Takahashi K, Nagata S. Functional expression and tissue distribution of a novel receptor for VIP. Neuron 1992; 8: 811-819.
58. Tseng J, O'Dorisio M S. Mechanism of vasoactive intestinal peptide (VIP)-mediated immunoregulation. In: Goetzl E J, Spector N H, eds. Neuroimmune networks: Physiology and diseases. New York: Alan R. Liss Inc, 1989: 95-115.
59. Nishizuka Y. Studies and perspectives of protein kinase C. Science 1986; 233: 305-308.
60. Beckner S K, Farrar W L. Potentiation of lymphokine-activated killer cell differentiation and lymphocyte proliferation by stimulation of protein kinase C or inhibition of adenylate cyclase. J Immunol 1988; 140: 208-211.
61. Bareis D L, Hirata F, Schiffman E, Axelrod J. Phospholipid metabolism, calcium flux and the receptor mediated induction of chemotaxis in rabbit neutrophils. J Cell Biol 1982; 93: 690-697.
62. Snyderman R, Pike M C. Chemoattractant receptors on phagocytic cells. Annu Rev Immunol 1984; 2: 257-281.
63. Shelly J, Hoff S E Effect of non-steroidal anti-inflammatory drugs on isolated human polymorphonuclear leukocytes (PMN). Gen Pharmacol 1989; 20: 329-334.
64. Isaad C, Ventura M A, Thomopoulos P. Biphasic regulation of macrophage attachment by activators of cyclic adenosine monophosphate-dependent kinase and protein kinase C. J Cell Physiol 1989; 140: 317-322.
65. Chakder S, Rattan S. The entire vasoactive intestinal polypeptide molecule is required for the activation of the vasoactive intestinal polypeptide: functional and binding studies on opossum internal and sphincter smooth muscle. J Pharmacol Exp Ther 1993; 266: 392-399.
66. Rodriguez-Pena M S, Guijarro L G, Prieto J C. Vasoactive intestinal peptide receptor antagonist in rat seminal vesicle membranes. Eur J Pharmacol 1991; 208: 207-212.
67. Martinez C, Delgado M, Gomariz R P, Ganea D. Vasoactive intestinal peptide and pituitary adenylate cyclase-activating polypeptide-38 inhibit IL-10 production in murine T lymphocytes. J Immunol 1996; 156: 4128-4136.